8V17 | pdb_00008v17

HIV-CA Disulfide linked Hexamer with inhibitor bound - exploration of a benzothiazole


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.50 Å
  • R-Value Free: 
    0.171 (Depositor), 0.172 (DCC) 
  • R-Value Work: 
    0.142 (Depositor), 0.142 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

"Pseudosubstrate Envelope"/Free Energy Perturbation-Guided Design and Mechanistic Investigations of Benzothiazole HIV Capsid Modulators with High Ligand Efficiency.

Xu, S.Wang, S.Zhou, Y.Foley, N.Sun, L.Walsham, L.Tang, K.Shi, D.Shi, X.Zhang, Z.Jiang, X.Gao, S.Liu, X.Pannecouque, C.Goldstone, D.C.Dick, A.Zhan, P.

(2024) J Med Chem 67: 19057-19076

  • DOI: https://doi.org/10.1021/acs.jmedchem.4c01544
  • Primary Citation of Related Structures:  
    8V17

  • PubMed Abstract: 

    Based on our proposed "pseudosubstrate envelope" concept, 25 benzothiazole-bearing HIV capsid protein (CA) modulators were designed and synthesized under the guidance of free energy perturbation technology. The most potent compound, IC-1k , exhibited an EC 50 of 2.69 nM against HIV-1, being 393 times more potent than the positive control PF74. Notably, IC-1k emerged as the highest ligand efficiency (LE = 0.32) HIV CA modulator, surpassing that of the approved drug lenacapavir (LE = 0.21). Surface plasmon resonance assay and crystallographic analysis confirmed that IC-1k targeted HIV-1 CA within the chemical space of the "pseudosubstrate envelope". Further mechanistic studies revealed a dual-stage inhibition profile: IC-1k disrupted early-stage capsid-host-factor interactions and promoted late-stage capsid misassembly. Preliminary pharmacokinetic evaluations demonstrated significantly improved metabolic stability in human liver microsomes for IC-1k ( T 1/2 = 91.3 min) compared to PF74 ( T 1/2 = 0.7 min), alongside a favorable safety profile. Overall, IC-1k presents a promising lead compound for further optimization.


  • Organizational Affiliation
    • Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan, Shandong 250012, PR China.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Spacer peptide 1229Human immunodeficiency virus 1Mutation(s): 4 
Gene Names: gag
UniProt
Find proteins for Q72497 (Human immunodeficiency virus type 1)
Explore Q72497 
Go to UniProtKB:  Q72497
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ72497
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.50 Å
  • R-Value Free:  0.171 (Depositor), 0.172 (DCC) 
  • R-Value Work:  0.142 (Depositor), 0.142 (DCC) 
Space Group: P 6
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 90.902α = 90
b = 90.902β = 90
c = 56.468γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2024-12-11
    Type: Initial release